Effect of macrophages transduced with an adenoviral vector expressing interleukin-12 in prostate cancer
Effect of macrophages transduced with an adenoviral vector expressing interleukin-12 in prostate cancer
批准号:
15591712
负责人:
IWAMURA Masatsugu
金额:
$1.73万
依托单位:
依托单位国家:
日本
项目类别:
Grant-in-Aid for Scientific Research (C)
财政年份:
2003
资助国家:
日本
项目状态:
已结题
起止时间:
2003 至 2004
中文摘要
对于晚期前列腺癌,标准疗法是雄激素消融术,这在很大程度上是姑息性的,开发对全身性疾病有效的额外疗法来补充目前对局部前列腺癌的治疗是至关重要的。新的方法,如免疫基因治疗,为实现这些目标提供了机会。我们利用178-2 BMA小鼠前列腺癌模型研究了小鼠IL-12重组腺病毒载体(AdmIL-12)转导巨噬细胞的效果。admil -12转导的巨噬细胞在体外分泌IL-12,在任何MOI下细胞数量均无显著差异。未感染的巨噬细胞和adβ - gal感染的巨噬细胞在24小时和48小时产生非常低水平的IL-12,而在admil -12感染的巨噬细胞中检测到mIL-12分泌的剂量和时间依赖性增加。细胞分析显示,与未感染的巨噬细胞相比,admil -12感染的巨噬细胞表面MHC I类、II类分子和F4/80抗原的表达增加了2倍。ad β - gal感染的巨噬细胞与未感染的巨噬细胞相似,只是MHC II类表达增加。根据这些结果,我们已经成功地证明了用腺病毒载体对小鼠腹膜渗出巨噬细胞进行基因修饰,这种治疗方法有望诱导大量的全身抗肿瘤免疫反应。下一步,为了确定AdmIL-12转导的巨噬细胞可能的治疗活性,我们将使用转移性前列腺癌的原位小鼠模型建立临床前实验。
英文摘要
For advanced prostate cancer, the standard therapy is androgen ablation, which largely palliative and it is critical to develop additional therapies that are effective against systemic disease to complement current treatments for localized prostate cancer. Novel approaches, such as immunogene therapy, provide opportunities to achieve these goals.We investigated the efficacy of macrophages transduced with murine IL-12 recombinant adenoviral vector (AdmIL-12) using the 178-2 BMA mouse prostate cancer model. AdmIL-12-transduced macrophages secreted IL-12 in vitro and there were no significant differences in cell number at any MOI. Uninfected macrophages and Adβgal-infected macrophages produced very low levels of IL-12 at 24h and 48h, whereas a dose- and time- dependent increase in secretion of mIL-12 was detected in the AdmIL-12-infected macrophages. Cytometric analysis showed that AdmIL-12-infected macrophages had an 2 fold increase in surface expression of MHC class I and II molecules and F4/80 antigen compared with uninfected macrophages. Adβgal-infected macrophages were similar to uninfected macrophages except that increased MHC class II expression was observed. According to these results, we have demonstrated successful genetic modification of murine peritoneal exudates macrophages with adenoviral vectors and this therapeutic approach may induced substantial systemic antitumor immunological responses, hopefully. For next step to determine possible therapeutic activities AdmIL-12 transduced macrophages, we are going to set up preclinical experiment using an orthotopic mouse model of metastatic prostate cancer.
期刊论文(19)
专著(0)
科研奖励(0)
会议论文
登录
查看更多内容
DOI:
--
发表时间:
期刊:
Gene Therapy in Cancer (accepted)
影响因子:
--
作者:
[Matsumoto K, Irie A, et al.]
通讯作者:
et al.
DOI:
10.1016/j.urology.2005.01.051
发表时间:
2005-07-01
期刊:
UROLOGY
影响因子:
2.1
作者:
[Satoh, T, Matsumoto, K, Baba, S]
通讯作者:
Baba, S
Immunomodulatory gene therapy for prostate cancer : Current outcome and future directions.
前列腺癌的免疫调节基因治疗:当前结果和未来方向。
DOI:
--
发表时间:
期刊:
TRANSWORLD RESEARCH NETWORK (in press)
影响因子:
--
作者:
[Satoh T, Iwamura M et al.]
通讯作者:
Iwamura M et al.
佐藤 威文 他: "In situ gene therapy for prostate cancer."Current Gene Therapy.. (in press).
Takefumi Sato 等人:“前列腺癌的原位基因治疗。”当前基因治疗..(正在印刷中)。
DOI:
--
发表时间:
期刊:
影响因子:
--
作者:
[]
通讯作者:
Laparoscopic pyeloplasty for ureteropelvic junction obatruction : Outcome of initial 12 procedures.
腹腔镜肾盂成形术治疗肾盂输尿管连接部梗阻:最初 12 次手术的结果。
DOI:
--
发表时间:
2004
期刊:
Int J Urol. 11
影响因子:
--
作者:
[Iwamura M, Soh S, et al.]
通讯作者:
et al.
共 8 条
Proteomic analysis of cyst fluid associated with renal cell carcinoma
-
批准号:22591776
-
项目类别:Grant-in-Aid for Scientific Research (C)
-
资助金额:$2.83万
-
财政年份:2010
-
负责人:IWAMURA Masatsugu
-
依托单位:
Searching for new biomarkers of Renal cell carcinoma based on proteomic approach
-
批准号:18591772
-
项目类别:Grant-in-Aid for Scientific Research (C)
-
资助金额:$2.66万
-
财政年份:2006
-
负责人:IWAMURA Masatsugu
-
依托单位:
Usefulness of parathyroid hormone-related protein as a histological marker for detecting the pre-neoplastic lesion in the prostate
-
批准号:08671842
-
项目类别:Grant-in-Aid for Scientific Research (C)
-
资助金额:$1.15万
-
财政年份:1996
-
负责人:IWAMURA Masatsugu
-
依托单位:
国内基金
海外基金
支链氨基酸代谢紊乱调控“Adipocytes - Macrophages Crosstalk”诱发2型糖尿病脂肪组织功能和结构障碍的作用及机制
-
批准号:81970721
-
项目类别:面上项目
-
资助金额:55.0万元
-
批准年份:2019
-
负责人:陶凌
-
依托单位: